Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

Shaji K Kumar, Joseph R Mikhael, Francis K. Buadi, David M Dingli, Angela Dispenzieri, Rafael Fonseca, Morie Gertz, Philip R. Greipp, Suzanne R. Hayman, Robert A. Kyle, Martha Lacy, John A. Lust, Craig B. Reeder, Vivek Roy, Stephen J Russell, Kristen E. Detweiler Short, Alexander Keith Stewart, Thomas Elmer Witzig, Steven R. Zeldenrust, Robert J. DaltonS Vincent Rajkumar, Peter Leif Bergsagel

Research output: Contribution to journalArticle

192 Citations (Scopus)

Abstract

Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people each year and is the second most common hematologic malignancy. It is part of a spectrum of monoclonal plasma cell disorders, many of which do not require active therapy. During the past decade, considerable progress has been made in our understanding of the disease process and factors that influence outcome, along with development of new drugs that are highly effective in controlling the disease and prolonging survival without compromising quality of life. Identification of well-defined and reproducible prognostic factors and introduction of new therapies with unique modes of action and impact on disease outcome have for the first time opened up the opportunity to develop risk-adapted strategies for managing this disease. Although these risk-adapted strategies have not been prospectively validated, enough evidence can be gathered from existing randomized trials, subgroup analyses, and retrospective studies to develop a working framework. This set of recommendations represents such an effort - the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence.

Original languageEnglish (US)
Pages (from-to)1095-1110
Number of pages16
JournalMayo Clinic Proceedings
Volume84
Issue number12
DOIs
StatePublished - 2009

Fingerprint

Multiple Myeloma
Guidelines
Plasma Cell Neoplasms
Therapeutics
Hematologic Neoplasms
Plasma Cells
Retrospective Studies
Quality of Life
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Management of newly diagnosed symptomatic multiple myeloma : Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. / Kumar, Shaji K; Mikhael, Joseph R; Buadi, Francis K.; Dingli, David M; Dispenzieri, Angela; Fonseca, Rafael; Gertz, Morie; Greipp, Philip R.; Hayman, Suzanne R.; Kyle, Robert A.; Lacy, Martha; Lust, John A.; Reeder, Craig B.; Roy, Vivek; Russell, Stephen J; Detweiler Short, Kristen E.; Stewart, Alexander Keith; Witzig, Thomas Elmer; Zeldenrust, Steven R.; Dalton, Robert J.; Rajkumar, S Vincent; Bergsagel, Peter Leif.

In: Mayo Clinic Proceedings, Vol. 84, No. 12, 2009, p. 1095-1110.

Research output: Contribution to journalArticle

@article{09e9e36ba08449098f4bb4881676d0dd,
title = "Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines",
abstract = "Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people each year and is the second most common hematologic malignancy. It is part of a spectrum of monoclonal plasma cell disorders, many of which do not require active therapy. During the past decade, considerable progress has been made in our understanding of the disease process and factors that influence outcome, along with development of new drugs that are highly effective in controlling the disease and prolonging survival without compromising quality of life. Identification of well-defined and reproducible prognostic factors and introduction of new therapies with unique modes of action and impact on disease outcome have for the first time opened up the opportunity to develop risk-adapted strategies for managing this disease. Although these risk-adapted strategies have not been prospectively validated, enough evidence can be gathered from existing randomized trials, subgroup analyses, and retrospective studies to develop a working framework. This set of recommendations represents such an effort - the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence.",
author = "Kumar, {Shaji K} and Mikhael, {Joseph R} and Buadi, {Francis K.} and Dingli, {David M} and Angela Dispenzieri and Rafael Fonseca and Morie Gertz and Greipp, {Philip R.} and Hayman, {Suzanne R.} and Kyle, {Robert A.} and Martha Lacy and Lust, {John A.} and Reeder, {Craig B.} and Vivek Roy and Russell, {Stephen J} and {Detweiler Short}, {Kristen E.} and Stewart, {Alexander Keith} and Witzig, {Thomas Elmer} and Zeldenrust, {Steven R.} and Dalton, {Robert J.} and Rajkumar, {S Vincent} and Bergsagel, {Peter Leif}",
year = "2009",
doi = "10.4065/mcp.2009.0603",
language = "English (US)",
volume = "84",
pages = "1095--1110",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "12",

}

TY - JOUR

T1 - Management of newly diagnosed symptomatic multiple myeloma

T2 - Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

AU - Kumar, Shaji K

AU - Mikhael, Joseph R

AU - Buadi, Francis K.

AU - Dingli, David M

AU - Dispenzieri, Angela

AU - Fonseca, Rafael

AU - Gertz, Morie

AU - Greipp, Philip R.

AU - Hayman, Suzanne R.

AU - Kyle, Robert A.

AU - Lacy, Martha

AU - Lust, John A.

AU - Reeder, Craig B.

AU - Roy, Vivek

AU - Russell, Stephen J

AU - Detweiler Short, Kristen E.

AU - Stewart, Alexander Keith

AU - Witzig, Thomas Elmer

AU - Zeldenrust, Steven R.

AU - Dalton, Robert J.

AU - Rajkumar, S Vincent

AU - Bergsagel, Peter Leif

PY - 2009

Y1 - 2009

N2 - Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people each year and is the second most common hematologic malignancy. It is part of a spectrum of monoclonal plasma cell disorders, many of which do not require active therapy. During the past decade, considerable progress has been made in our understanding of the disease process and factors that influence outcome, along with development of new drugs that are highly effective in controlling the disease and prolonging survival without compromising quality of life. Identification of well-defined and reproducible prognostic factors and introduction of new therapies with unique modes of action and impact on disease outcome have for the first time opened up the opportunity to develop risk-adapted strategies for managing this disease. Although these risk-adapted strategies have not been prospectively validated, enough evidence can be gathered from existing randomized trials, subgroup analyses, and retrospective studies to develop a working framework. This set of recommendations represents such an effort - the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence.

AB - Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people each year and is the second most common hematologic malignancy. It is part of a spectrum of monoclonal plasma cell disorders, many of which do not require active therapy. During the past decade, considerable progress has been made in our understanding of the disease process and factors that influence outcome, along with development of new drugs that are highly effective in controlling the disease and prolonging survival without compromising quality of life. Identification of well-defined and reproducible prognostic factors and introduction of new therapies with unique modes of action and impact on disease outcome have for the first time opened up the opportunity to develop risk-adapted strategies for managing this disease. Although these risk-adapted strategies have not been prospectively validated, enough evidence can be gathered from existing randomized trials, subgroup analyses, and retrospective studies to develop a working framework. This set of recommendations represents such an effort - the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence.

UR - http://www.scopus.com/inward/record.url?scp=72949085546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72949085546&partnerID=8YFLogxK

U2 - 10.4065/mcp.2009.0603

DO - 10.4065/mcp.2009.0603

M3 - Article

C2 - 19955246

AN - SCOPUS:72949085546

VL - 84

SP - 1095

EP - 1110

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 12

ER -